Abbvie INC 10-Q quarterly reports

AbbVie Inc. announced robust second-quarter 2026 financial results, driven by strong performance in immunology and neuroscience, alongside a significant acquisition of Apogee Therapeutics.

AbbVie reports Q1 2026 net revenues of $15.0 billion, driven by strong growth in Skyrizi and Rinvoq, despite ongoing Humira biosimilar competition.

AbbVie reports robust third-quarter 2025 revenue growth driven by immunology and neuroscience, but net earnings significantly declined due to substantial R&D investments and impairment charges.

AbbVie reports robust revenue growth driven by new immunology and neuroscience drugs, offsetting Humira's biosimilar impact, despite a dip in net earnings due to contingent consideration adjustments.

AbbVie's Q1 2025 results showcase revenue growth driven by key products like Skyrizi and Rinvoq, alongside strategic acquisitions and pipeline advancements.

AbbVie's Q3 2024 results show a 3% increase in net revenue and diluted earnings per share of $0.88, impacted by recent acquisitions and ongoing market dynamics.

AbbVie's second-quarter results show revenue growth driven by key products, offset by Humira biosimilar competition and increased expenses related to recent acquisitions.

AbbVie's first quarter 2024 results show a slight revenue increase and significant earnings growth, driven by key product performance and strategic acquisitions.